
Metagenomi Inc (MGX) Stock Forecast & Price Target
Metagenomi Inc (MGX) Analyst Ratings
Bulls say
Metagenomi Inc. has demonstrated significant progress in its gene editing capabilities, achieving durable Factor VIII (FVIII) levels at 80% over a 19-month period in non-human primates, indicating the potential effectiveness of its therapies in treating Hemophilia A. The company's proprietary metagenomics-derived genome editing toolbox, which includes advanced systems for both small and large gene edits, positions it favorably in a competitive biotechnology landscape. Furthermore, Metagenomi's commitment to developing its wholly-owned pipeline while also exploring out-licensing opportunities for ex vivo cell therapy enhances its revenue potential and growth prospects in addressing a range of serious genetic disorders.
Bears say
Metagenomi Inc reported a substantial net loss of $19.9 million, equivalent to $0.54 per share, for the second quarter of 2025, indicating financial strain. The company faces significant risks related to potential delays in advancing its pipeline candidates and the possibility of generating unfavorable clinical data, particularly for its critical programs targeting Hemophilia A and TTR. Additionally, concerns regarding long-term dilution risk may further exacerbate investor apprehension regarding the company's financial health and stock performance.
This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.
Metagenomi Inc (MGX) Analyst Forecast & Price Prediction
Start investing in Metagenomi Inc (MGX)
Order type
Buy in
Order amount
Est. shares
0 shares